No phaseStatus unknownHealthspan endpoint

Effects of Liraglutid, Dapagliflozin and Acarbose on the Cognitive Function, Olfactory Function, and Odor-induced Brain Activation in Overweight/Obese T2DM Patients Controlled Inadequately With Metformin Monotherapy.

A Prospective, Randomized, Open Label, Parallel, 16-week Study to Explore and Evaluate the Therapeutic Effects of Liraglutid, Dapagliflozin and Acarbose on the Cognitive Function, Olfactory Function, and Odor-induced Brain Activation in Overweight/Obese Patients With T2DM Inadequately Controlled With Metformin Monotherapy.

Sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (Academic or other)
Enrollment
87 planned
Conditions
Type 2 Diabetes Mellitus; Obesity; Cognitive Impairment
Interventions
Liraglutid; Dapagliflozin; Acarbose
Ages
adults, older adults
Registry
NCT03961659

Full record on ClinicalTrials.gov

From the registry

This is a prospective, randomized, open label, parallel, 16-week study to explore and evaluate the therapeutic effects of liraglutid, dapagliflozin and acarbose on the cognitive function, olfactory function, and odor-induced brain activation in overweight/obese patients with type 2 diabetes mellitus(T2DM) inadequately controlled with metformin monotherapy.

Primary outcomes

  • Change of olfactory brain activation by fMRI

History

  1. Study completion

  2. Primary completion

  3. Registered

  4. Started

Papers citing this trial